Valuation: Clene Inc.

Market Cap 74.75M 65.5M 60.81M 55.87M 105M 7.21B 107M 724M 284M 3.53B 281M 275M 12.19B P/E 2026 *
-3.28x
P/E 2027 * -3.97x
Enterprise Value 61.35M 53.76M 49.91M 45.86M 86.41M 5.92B 87.69M 595M 233M 2.9B 230M 225M 10.01B EV / Sales 2026 *
296x
EV / Sales 2027 * 2.26x
Free-Float
82.94%
Yield 2026 *
-
Yield 2027 * -
1 day-0.51%
1 week-3.32%
Current month-5.44%
1 month-1.19%
3 months-11.42%
6 months+7.38%
Current year-0.85%
1 week 5.57
Extreme 5.5701
6.13
1 month 5.57
Extreme 5.5701
6.55
Current year 3.88
Extreme 3.88
8.67
1 year 3.25
Extreme 3.25
13.5
3 years 2.28
Extreme 2.2801
16.12
5 years 2.28
Extreme 2.2801
196.8
10 years 2.28
Extreme 2.2801
356.4
Manager TitleAgeSince
Chief Executive Officer 59 2013-03-31
Chief Tech/Sci/R&D Officer 67 2012-12-31
Director of Finance/CFO 57 2022-01-31
Director TitleAgeSince
Director/Board Member 78 2013-02-28
Chairman 65 2021-05-18
Director/Board Member 49 2020-11-30
Date Insider Type Main position Quantity % Market Cap.
6/11/26 Free

Chief Financial Officer

15,000 0.1174%
6/11/26 Free

Chief Executive Officer

65,000 0.5087%
6/11/26 Free

Founder

45,000 0.3522%
Change 5-day change 1-year change 3-year change Capi.($)
-0.51%-3.32%+52.76%-62.69% 74.75M
-0.43%-1.26%+52.13%+85.69% 55.57B
-0.24%-0.37%+57.02%+54.21% 54.26B
-0.54%-0.17%-17.60%-14.20% 23.35B
-1.82%-2.89%+3.61%+421.21% 23.54B
+0.05%+1.68%+38.71%-4.57% 20.32B
+3.16%+2.74%+37.33%-31.36% 17.36B
+1.08%+3.77%+36.92%+593.96% 15.59B
+0.43%-1.67%+166.53%+299.61% 14.96B
-2.03%-1.03%+23.63%+176.42% 14.11B
Average -0.08%-0.75%+45.10%+151.83% 23.91B
Weighted average by Cap. -0.18%-0.24%+43.92%+137.49%

Financials

2026 *2027 *
Net sales 207K 182K 169K 155K 292K 20.01M 296K 2.01M 787K 9.79M 779K 762K 33.83M 23.64M 20.72M 19.23M 17.67M 33.3M 2.28B 33.79M 229M 89.68M 1.12B 88.76M 86.85M 3.86B
Net income -25.09M -21.99M -20.41M -18.76M -35.34M -2.42B -35.86M -243M -95.17M -1.18B -94.2M -92.17M -4.09B -27.55M -24.14M -22.41M -20.59M -38.8M -2.66B -39.37M -267M -104M -1.3B -103M -101M -4.49B
Net Debt -13.4M -11.74M -10.9M -10.02M -18.87M -1.29B -19.15M -130M -50.82M -633M -50.3M -49.22M -2.19B -21.4M -18.75M -17.41M -16M -30.14M -2.06B -30.58M -207M -81.16M -1.01B -80.33M -78.6M -3.49B
Logo Clene Inc.
Clene Inc. is a clinical-stage pharmaceutical company, which is engaged in discovery, development, and commercialization of novel clean-surfaced nanotechnology (CSN) therapeutics. The CSN therapeutics are comprised of atoms of transition elements that, when assembled in nanocrystal form, possess unusually high, unique catalytic activities that do not present in those same elements in bulk form. CNM-Au8, the lead drug asset, is a concentrated aqueous suspension of catalytically active, clean-surfaced, faceted gold nanocrystals for the treatment of ALS, MS, and PD. CNM-Au8's mechanism of action targets mitochondrial dysfunction by catalyzing the production of nicotinamide adenine dinucleotide. Its CNM-ZnAg is an antiviral and antibacterial agent comprised of zinc (Zn2+) and silver (Ag+) ions in an aqueous solution to treat infectious disease and to provide immune support for symptom resolution.
Employees
78
Date Price Change Volume
26-07-22 US$5.820 -0.51% 42,791
26-07-21 US$5.850 +2.09% 72,499
26-07-20 US$5.730 -3.21% 39,992
26-07-17 US$5.920 +4.04% 83,174
26-07-16 US$5.690 -5.48% 97,068
Trader
Investor
-
Global
-
Quality
-
ESG MSCI
-
Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
5
Last Close Price
5.850USD
Average target price
32.20USD
Spread / Average Target
+450.43%

Quarterly revenue - Rate of surprise

  1. Stock Market
  2. Stocks
  3. CLNN Stock